Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial

This post-hoc follow up analysis at 90 days found a reduction in risk of invasive or non-invasive ventilation or death for tocilizumab vs usual care in those with CRP >15.0 mg/dL (18% vs 57%, HR 0.18, 95%CI 0.06-0.59), but there was no difference in those with CRP <15.0 mg/dL.

Source:

JAMA Internal Medicine